ArticleTranslational lung cancer research2025
Predictors of survival and recurrence patterns following definitive chemoradiotherapy in stage III non-small cell lung cancer-a retrospective cohort study.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Significant improvement in overall survival with postoperative traditional Chinese medicine in stage I lung adenocarcinoma: a real-world retrospective cohort study.Translational lung cancer research · 2026Article
- Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.Translational lung cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemoradiotherapy (CRT) is regarded as the treatment of choice for inoperable stage III non-small cell lung cancer (NSCLC) patients. Despite the curative intent, recurrence is frequent, and overall prognosis is poor. Thus, there is a need for clinical biomarkers to better predict outcome and to optimize treatment and follow-up. The aim of this study was to characterize a large cohort of real-world stage III NSCLC patients who received CRT with curative intent and to define parameters that could predict recurrence patterns, overall survival (OS) and survival time from recurrence. Methods: This study is based on a cohort of 193 stage III NSCLC patients receiving CRT with curative intent in mid-Sweden during the years 2009-2018. Data was retrospectively collected from medical records. Clinical parameters, recurrence patterns, salvage treatment, histological and molecular data were analyzed and correlated to outcome. Results: Median follow-up was 52 months, with a median OS of 33 months. Most patients (66%) progressed, commonly within the first 3 years following CRT. Performance status and common blood markers at recurrence were associated with worse survival. The presence of driver mutations [epidermal growth factor receptor ( Conclusions: Routine diagnostic parameters can be used to predict survival and recurrence patterns in patients receiving curative CRT. Additionally, salvage treatment with immunotherapy was the strongest factor associated with longer survival after disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.